Struggling Greenwood biotech firm finds buyer
Elona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development incentives, says it has solution to its financial problems.
Elona Biotechnologies Inc., which has been struggling to repay Greenwood for more than $8 million in economic development incentives, says it has solution to its financial problems.
House Republican leaders toured an Indianapolis preschool Wednesday, one day before the House Education Committee takes up a proposal to give preschool vouchers to low-income families in a small number of cases.
With Eli Lilly and Co. set to see patents expire on its best-selling drug at year’s end, it is in the company’s interest to say its pipeline is about to produce new drugs. But the Indianapolis drugmaker may be in a position to submit five new drugs for regulatory approval this year.
Indiana University Health Morgan Hospital in Martinsville stopped delivering babies on Friday and instead will direct pregnant women to IU Health Bloomington Hospital, which is a 30-minute drive farther south. In 2012, only 3 percent of deliveries at Bloomington Hospital were for moms from Morgan County. But IU Health made the change because the hospital in Martinsville was delivering only 218 of the 1,200 annual births in Morgan County, according to an evaluation by the American College of Obstetrics and Gynecology. The group recommends a hospital have at least 300 births in order to continue its obstetrics program. The change is also being made because many of the women seeking obstetric services at IU Morgan are high-risk patients and the hospital does not have the facilities to serve them, said Amy Wozniak, IU Health Morgan's director of public relations, in a statement. IU Health Bloomington Hospital delivers about 1,900 babies each year. “We understand this affects our community as well as some IU Health Morgan Hospital employees. We believe, however, that this decision is best for our patients,” said Doug Puckett, CEO of IU Health Morgan Hospital.
Indianapolis-based Hall Render Killian Heath & Lyman PC, the nation’s largest health-care-focused law firm, has officially launched a pharmacy practice. Though the practice area is new, several lawyers within the firm have used their pharmacy-related knowledge and experience to serve clients for several years, said John Hall, the firm’s president and managing partner. The lawyers typically counsel retail and mail-order pharmacies, hospitals and long-term-care providers on a variety of issues: regulatory compliance and enforcement support, development and maintenance of compliance programs, Medicare and Medicaid reimbursement, private-payer reimbursement, fraud and abuse, and litigation. Hall Render’s pharmacy practice is led by Susan Bizzell, a shareholder of the firm, and is the latest addition to the firm's more than 60 health-care-related specialties. The pharmacy practice consists of about 10 lawyers. With 97 local attorneys, Hall Render is ranked as the city’s seventh-largest law firm, according to IBJ’s most recent statistics.
Indianapolis-based Pearl IRB LLC, a life sciences consultancy operating as Pearl Pathways, announced Jan. 29 that it plans to add 38 jobs by 2016 as part of a $355,000 expansion. The company, in Indiana University’s Emerging Tech Center near the Central Canal, will use the investment to lease and equip a 2,000-square-foot facility at 29 E. McCarthy St. Pearl Pathways plans to move in March and is hiring additional regulatory-affairs, quality-compliance and clinical-trial specialists. The Indiana Economic Development Corp. said it will provide Pearl Pathways up to $750,000 in performance-based tax credits and up to $75,000 in training grants based on the company's job-creation plans. Founded in 2010 by former Eli Lilly and Co. employees Diana Caldwell and Gretchen Miller Bowker, Pearl Pathways provides research and product development services for drug, biologic and medical device companies.
Zimmer Holdings Inc. predicted revenue and profit will pick up steam in 2013 after its fourth-quarter profit fell 2 percent due to large accounting charges. The Warsaw-based maker of orthopedic implants said it expects revenue to grow this year 2.5 percent to 4.5 percent, when adjusted for foreign currency fluctuations. It expects earnings per share, excluding special charges, to range between $5.65 and $5.85. Those results would mark growth of 7 percent to 10 percent over last year’s adjusted earnings per share of $5.30. In the fourth quarter, Zimmer’s reduced profits still beat estimates of Wall Street analysts. Zimmer earned $152.8 million, or 88 cents per share, in the quarter. The company took a $96 million charge to write down the value of its U.S. spine business, which it says is pressured by lower utilization and lower prices. Excluding that charge and $69 million in other special charges, Zimmer would have earned $1.51 per share. Analysts expected $1.49, according to a survey by Thomson Reuters. For all of 2012, Zimmer’s profit fell 1 percent, to $755 million, from the previous year. Excluding special charges, the company would have earned $932.5 million, an increase of 3 percent. Revenue totaled $4.47 billion, virtually unchanged. Wall Street analysts have said 2013 could be a “breakout” year for Zimmer, which has suffered through several years of slow growth. However, they also worry the company is more exposed than its peers to changes coming in 2014 from the U.S. Patient Protection & Affordable Care Act. Zimmer shares have risen 23 percent in the past 12 months.
Suzanne Clifford has been named executive vice president of behavioral health at Community Health Network, beginning Feb. 25. She replaces Eric Crouse, who is retiring after nearly 34 years at Community. Clifford most recently has led Inspiring Transformations Inc., an Indianapolis-based consulting firm she founded that focused on the delivery of mental health and substance abuse care. Before that, Clifford was director of the Indiana Division of Mental Health and Addiction, and also served stints at Eli Lilly and Co. and General Motors Corp. She holds a bachelor’s in industrial and systems engineering from The Ohio State University and an MBA from Indiana University.
St. Vincent Health has appointed Dr. Craig Wilson chief medical officer of St. Vincent Medical Center Northeast, which is adding 50 inpatient beds and will change its name to St. Vincent Fishers Hospital on April 8. Wilson will remain executive director of hospitalist services at St. Vincent Indianapolis Hospital. Wilson completed his medical degree at the University of Queensland, Australia.
The Indiana Medical Device Manufacturers Council appointed Peggy Welch as its executive director, effective immediately. Welch was a Democratic state legislator from Bloomington for 14 years and works part time as an oncology nurse at the Indiana University Health Bloomington Hospital.
Dr. Nahid Shahrooz has joined the newly established Franciscan Physician Network Dermatology Specialists. Formerly associated with Shahrooz Dermatology and the Indianapolis Institute for Plastic Surgery, she specializes in the surgical removal of skin tumors, cancers and lesions. Shahrooz earned her medical degree at Mashad Medical School in Iran.
Dr. Janice Bilby has joined Franciscan Physician Network Greenwood Parke Family Medicine. Bilby received her undergraduate degree in biology from Ball State University and her medical degree from the Indiana University School of Medicine.
The state's agriculture department under new Gov. Mike Pence is planning a push into the science behind food production by trying to build a network of university and commercial researchers for what's being called an Agriculture Innovation Corridor.
Frustrated by up-and-down state funding for startup life sciences companies, industry leaders are talking up a plan to create a dedicated funding stream that could total $30 million a year.
Competitive, growing public companies that develop job opportunities and invest in the needs and resources of our community have a long-standing ripple effect.
I am proud to relate that Pawel Fludzinski, Ph.D. recently published his first crossword puzzle in The New York Times. Pawel has worked at Eli Lilly and Co. for more than 28 years with the last 20 years being in executive level leadership positions. He has a Ph.D. in synthetic organic chemistry, but never mind that: He shares with me a love for construction of crossword puzzles.
Indianapolis-based Pearl Pathways, founded by two former Eli Lilly employees, plans to move into new space in March and add the jobs by 2016.
Price increases and sales gains helped Eli Lilly and Co. offset declining revenue from its former blockbuster Zyprexa in the fourth quarter, allowing the company to beat analysts' expectations and raise its 2013 profit forecast.
The next time you’re shopping and the cashier asks you if you would like to receive e-mail notices of sales and specials, think of Bryan Wade.
The Franciscan Alliance hospital system has signed a deal with Philadelphia-based health insurer Cigna Corp. to offer an accountable care plan to Cigna’s customers in the Indianapolis area. Mishawaka-based Franciscan will use the same accountable care organization it formed in 2011 to work with the federal Medicare program. That organization includes Franciscan hospitals in Carmel, Indianapolis and Mooresville, as well as 600 physicians in central Indiana. Franciscan and Cigna will rely heavily on case managers, who will help patients, especially those with chronic diseases, navigate the health system. The case managers will use Cigna data to identify patients in need of such attention and will in some cases refer patients to Cigna’s health management and wellness programs.
Warsaw-based DePuy Orthopaedics Inc. kept selling an artificial hip implant even after the doctors it paid as consultants on the product had begun abandoning it and after the product had failed an internal test, according to internal company documents disclosed in a legal case and summarized by The New York Times. DePuy, a subsidiary of New Jersey-based Johnson & Johnson, recalled the troubled hip implant, called the Articular Surface Replacement, or ASR, in 2010. The company has been the target of 10,000 lawsuits filed by patients who had to receive a second hip implant after the ASR failed. The device has been prone to shedding large amounts of metallic debris inside patients. DePuy’s own internal estimates show they expected the ASR to fail in 40 percent of patients within five years of their hip-implant surgery.
Greenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, is running out of cash and struggling to find new investors. The company told Greenwood officials of its financial troubles earlier this month, which prompted the Greenwood Redevelopment Commission to vote Jan. 17 to declare Elona in default on $8.4 million of economic development incentives the city gave the company in 2010. Wendy Brewer, an attorney for the Greenwood Redevelopment Commission, said one potential investor in Elona wants the company’s exposure under the incentive programs altered as a condition of investing in Elona. “We’re continuing to talk to them,” Brewer said, adding that the company’s finances dictate that a decision be made in a couple of weeks. Greenwood loaned $6.4 million to help Elona build a 50,000-square-foot, $28 million insulin-production plant in Greenwood and hire 70 workers. The city also gave Elona $1.5 million to help it win approval for its insulin from the U.S. Food and Drug Administration and $500,000 for equipment. So far, Brewer said, Elona has made no progress on its jobs commitments. Elona, founded by a former Eli Lilly and Co. scientist, has made its business doing contract drug manufacturing for other firms. But its growth plans hinged on making a generic version of insulin, something that was not allowed in the United States until the 2010 passage of the Patient Protection & Affordable Care Act. That law called for a pathway for “biosimilar” versions of biotech drugs, including insulin. As it stands now, a drug such as Lilly’s Humulin insulin faces no generic competition even though its patent expired in 2001. Nearly a year ago, the FDA issued draft guidance on “biosimilar” drugs that indicated it would require additional clinical trials of a biosimilar drug. That means a company like Elona would have to spend significant money to test its drug in patients before the FDA would declare it similar to an existing insulin. Calls to Elona founders Ron and Donna Zimmerman were not returned Tuesday morning.
WellPoint Inc. ended the year on a high note, posting fourth-quarter sales and profit that exceeded Wall Street’s expectations. The Indianapolis-based health insurer earned $464 million, or $1.51 per share, in the three months ended Dec. 31, a 38-percent leap from the same quarter a year earlier. Excluding investment gains and one-time charges, WellPoint would have earned $1.03 per share. On that basis, analysts were expecting 95 cents per share. Membership in WellPoint’s health plans shot up nearly 8 percent in the fourth quarter to more than 36 million nationwide. That represented a net gain of more than 2.6 million customers. The increase was entirely attributable to WellPoint’s $4.9 billion acquisition of Virginia-based Amerigroup Corp., which added 2.7 million members in Medicaid plans. But the Blue Cross Blue Shield insurer on Wednesday gave analysts a conservative forecast for 2013, due in part to a daunting list of expenses it could face. WellPoint will spend roughly $300 million this year preparing for coverage expansions under the health care overhaul coverage and changes to its Medicare Advantage business. The insurer also expects to spend as much as $125 million integrating Amerigroup into its business, and it says it could take hits from flu claims, possible cuts to Medicare funding and an increase in health care use. Counting those expenses, WellPoint expects to earn at least $7.60 per share in 2013 compared to the $8.18 per share it earned last year.
St. Vincent Health will add air medical service at Rush Memorial Hospital in Rushville. The new StatFlight helicopter base, scheduled to open in late April or early May, will be St. Vincent's fourth helicopter base in Indiana. The others are located in Anderson, Danville, North Vernon and West Lafayette. St. Vincent contracts with PHI Air Medical LLC to operate its StatFlight air medical service.
The Community Health Network hospital system has created a new partnership with Indianapolis-based Lutheran Child and Family Services to provide treatment for children who have experienced trauma and are dealing with behavioral challenges. Indianapolis-based Community will help Lutheran manage the behavioral health services for children and adolescents at Lutherwood, a youth residential treatment facility, and Trinity House, a transitional group home for young men. The collaboration also will include community-based programs previously managed separately under Indianapolis-based Gallahue Community Mental Health Center and Lutheran. Lutheran will continue to offer spiritual care programs of its own for children and their families. Community serves more than 25,000 behavioral health patients each year. Its behavioral health unit employs more than 600 physicians, psychologists, advance practice nurses, psychiatric nurses, therapists, counselors, life skills specialists and care managers.
Greenwood-based Elona Biotechnologies Inc., which has been trying to bring a generic version of insulin to market, was declared in default on $8.4 million in incentives from the city of Greenwood.
The life sciences industry in Indiana employs 55,500 workers paying average wages of more than $88,500 per year, according to new figures released Tuesday by Indianapolis-based life sciences development group BioCrossroads.
Two new health clinics opened on the west side of Indianapolis last week. HealthNet Inc. opened a community health center on West 10th Street, providing primary, pediatric and OB/GYN care, as well as optomemtry, podiatry, behavioral health and social work services. Also, Community Health Network opened a medical office building in Speedway, which is part of its westward expansion after its acquisition of Westview Hospital on West 38th Street. The offices offer primary care, walk-in care, imaging, infusion therapy and occupational health services. Community also will work with the new Marian University College of Osteopathic Medicine to conduct training for medical residents in Speedway.
WellPoint Inc. is still considering former Amerigroup Corp. CEO James Carlson among several finalists to become CEO, Bloomberg News reported, citing a person familiar with the matter. The Indianapolis-based health insurer has delayed defining a role for Carlson, who joined WellPoint through its $4.9 billion acquisition of Amerigroup in December, because he is a contender for the top position, said the person, who asked for anonymity because the information is private. Retired Aetna Inc. CEO Ronald Williams also has been a leading candidate, according to people with knowledge of the deliberations. Carlson, 60, would replace Angela Braly, who was forced out in August amid investor complaints about the company's performance. Carlson built Amerigroup into one of the biggest insurers focused on the growing Medicaid sector. In an e-mail, Kristin Binns, a WellPoint spokeswoman, said the company wouldn’t comment on the CEO search. Maureen McDonnell, an Amerigroup spokeswoman, also declined to discuss the process or Carlson’s role. Katherine Mentus, a spokesman for Williams, declined to comment when reached by telephone. Analysts expect WellPoint to make a decision by the end of February.
Eli Lilly and Co. will have to conduct more studies of its experimental Alzheimer’s drug, but it is getting some outside help. Researchers at Brigham and Women’s Hospital in Boston chose Lilly’s drug solanezumab for a large federally funded study testing whether it's possible to prevent Alzheimer's disease in older people at high risk of developing it, according to the Associated Press. Lilly’s own studies of solanezumab found that it did not help people with moderate to severe Alzheimer's, but it showed some promise against milder disease. Researchers think it might work better if given before symptoms start. The new study will enroll 1,000 patients between age 70 and 85 who show a buildup of plaques in their brains but do not yet show signs of Alzheimer’s, including loss of memory and ability to do daily activities. Lilly’s solanezumab is also one of two drugs being studied in Alzheimer’s patients by researchers at Washington University. The other is made by the Genentech unit of Switzerland-based Roche Holding AG.
Indianapolis-based Defender Direct, a home security dealer, has opened an on-site health clinic, joining a number of other area employers that offer such services. Defender Direct’s 650 employees and their families now can receive primary care at the East 96th Street clinic, operated by Indianapolis-based OurHealth. Indianapolis-based MJ Insurance, which has helped such employers as Interactive Intelligence Inc. and others set up onsite clinics, brokered the deal.
Roche Diagnostics Corp. in Indianapolis ranks 89th on Fortune magazine’s latest annual list of the “100 Best Companies to Work For,” the magazine announced Thursday. In selecting Roche, the only Indiana company to appear on the list, Fortune cited its on-site medical clinic and fitness center, the company's $30,000 budget for intramural sports, and its health insurance plans tiered to income levels. The Indianapolis campus serves as the North American headquarters for the diagnostics business of Switzerland-based Roche Holding AG.
The Indiana Applied Research Enterprise already has received support from John Lechleiter, CEO of Indianapolis-based Eli Lilly and Co., as a place for collaboration between academic and industrial scientists.